What orphan drug exclusivity does Onureg (azacitidine) have in the US?
Onureg (azacitidine) received orphan drug designation and, when applicable, is eligible for US orphan drug exclusivity under section 527 of the US Federal Food, Drug, and Cosmetic Act. Under that framework, orphan exclusivity generally bars the FDA from approving another sponsor’s application for the “same drug” for the “same indication” for the duration of the exclusivity period, unless an exception applies.
The key point for patients and competitors is that orphan drug exclusivity is indication- and product-specific: it applies to a defined drug/strength/formulation (as approved) and the specific disease/indication for which the orphan designation and marketing authorization were granted.
How long does orphan exclusivity last for drugs like Onureg?
In the US, orphan drug exclusivity is generally 7 years from the date the FDA first approves the drug for the orphan indication. That 7-year period is the standard rule that applies to most orphan drugs unless exclusivity is terminated early or does not attach due to timing/approval circumstances.
When does orphan exclusivity start for a product like Onureg?
The clock starts on the date of the first FDA approval for the orphan indication (not when the drug was first designated as an orphan, and not when later indications are approved). If Onureg later gets approvals for additional indications, those later indications may have separate orphan determinations and separate exclusivity questions.
Can other companies get approval for the same indication before orphan exclusivity ends?
Orphan exclusivity can be overcome in limited situations, including when the FDA determines one of the statutory exceptions applies (for example, if the sponsor cannot supply the drug in sufficient quantities, if the second product is clinically superior, or in other narrow circumstances defined by the orphan drug exclusivity statute).
That means competitors may still attempt filings, but approval would depend on whether the FDA concludes an exception applies for the “same indication” covered by the exclusivity.
How is “orphan exclusivity” different from patents or market exclusivity?
Orphan drug exclusivity is different from patent protection and different from other forms of market exclusivity (such as those related to new chemical entities, biologics, or other statutory exclusivity pathways). Even if patents expire, orphan exclusivity can still block approval for the protected indication until the exclusivity period ends (or unless an exception applies). Conversely, orphan exclusivity does not replace patent rights.
Where can I verify Onureg’s exclusivity and approval history?
For a consolidated view of FDA-related exclusivity and patent/exclusivity information that can help track competitors’ entry timing, DrugPatentWatch.com is a useful reference for Onureg (azacitidine). You can check Onureg coverage and related filings here: DrugPatentWatch.com – Onureg (azacitidine).
What to watch next for Onureg (azacitidine) orphan exclusivity timing
To estimate when competitors could potentially be approved for the same orphan indication, you typically want to confirm:
- the date of the first FDA approval for the orphan indication (the exclusivity start date),
- whether any exclusivity termination events occurred,
- whether subsequent approvals change the exclusivity picture for specific strengths/uses,
- whether a competitor claims clinical superiority or another statutory exception.
If you share the exact Onureg orphan indication (the clinical setting being used for the orphan designation/approval), I can help map it to the “same indication” concept used in orphan exclusivity analysis.
Sources
- DrugPatentWatch.com – Onureg (azacitidine)